Buscar
Mostrando ítems 1-10 de 34
Reinforcing properties of fencamfamine: Involvement of dopamine and opioid receptors
(1995-01-17)
Fencamfamine (FCF) is a psychostimulant classified as an indirect dopamine agonist. The conditioning place preference (CPP) paradigm was used to investigate the reinforcing properties of FCF. After initial preferences had ...
Reinforcing properties of fencamfamine: Involvement of dopamine and opioid receptors
(1995-01-17)
Fencamfamine (FCF) is a psychostimulant classified as an indirect dopamine agonist. The conditioning place preference (CPP) paradigm was used to investigate the reinforcing properties of FCF. After initial preferences had ...
Síndrome das pernas inquietas: Diagnóstico e tratamento. Opinião de especialistas Brasileiros
(2007-09-01)
This article contains the conclusions of the November 17-18, 2006 meeting of the Brazilian Study Group of Restless Legs Syndrome (GBE-SPI) about diagnosis and management of restless legs syndrome (RLS). RLS is characterized ...
Síndrome das pernas inquietas: Diagnóstico e tratamento. Opinião de especialistas Brasileiros
(2007-09-01)
This article contains the conclusions of the November 17-18, 2006 meeting of the Brazilian Study Group of Restless Legs Syndrome (GBE-SPI) about diagnosis and management of restless legs syndrome (RLS). RLS is characterized ...
In vivo modulation of dopaminergic nigrostriatal pathways by cytisine derivatives: Implications for Parkinson's Disease
(2008)
Nicotinic acetylcholine receptor agonists are considered potential pharmacological agents for Parkinson's Disease treatment, due to their ability to improve experimental Parkinson symptomatology, reduce 3,4-dihydroxy-L-p ...
In vivo modulation of dopaminergic nigrostriatal pathways by cytisine derivatives: Implications for Parkinson's Disease
(ELSEVIER, 2008-07-28)
Nicotinic acetylcholine receptor agonists are considered potential pharmacological agents for Parkinson's Disease treatment, due to their ability to improve experimental Parkinson symptomatology, reduce 3,4-dihydroxy-L-p ...